Early predictors of substantial weight gain in bipolar patients treated with olanzapine

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 316-320

  Lipkovich, Ilya ^a   Citrome, Leslie ^b,c   Perlis, Roy ^d   Deberdt, Walter ^a   Houston, John P ^a   Ahl, Jonna ^a   Hardy, Thomas ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ETHNOLOGY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; OBESITY; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BODY MASS INDEX; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; WEIGHT GAIN;

EID: 33744485015     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000219916.88810.1c     Document Type: Article

References (24)

1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
2. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3):207-213.
3. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435.
4. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry. 1999;60(suppl 21):5-9.
5. Bellanger TM, Bray GA. Obesity related morbidity and mortality. J La State Med Soc. 2005;157:S42-S49. Spec No 1.
6. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701.
7. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108:324-332.
8. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry. 1988;153:214-217.
9. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363.
10. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in the treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481-489.
11. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
12. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-709.
13. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001;62(4):273-281.
14. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-1226.
15. Tohen M, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Paper presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
16. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011-1017.
17. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. July 2003;160(7):1263-1271.
18. National Institutes of Health. Clinical guideline on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6(suppl 2):51S-209S.
19. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-258.
20. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
21. Lemeshow S, Le Gall J-R. Modeling the severity of illness of ICU patients: a systems update. JAMA. 1994;272:1049-1055.
22. Fagiolini A, Frank E, Houck P, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry. 2002;63:528-533.
23. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. April 2001;62(4):231-238.
24. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. February 2001;62(2):92-100.